Category Press Releases

FDA Approves Uplizna® for the Treatment of Generalized Myasthenia Gravis in Adults

FDA Approves UPLIZNA® for Use in Adults with Generalized Myasthenia Gravis Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA® (inebilizumab-cdon) for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) and anti-muscle…

Read MoreFDA Approves Uplizna® for the Treatment of Generalized Myasthenia Gravis in Adults

CVS Health Revises Guidance, Showcases Business Strength, and Unveils Healthcare Reimagining Strategy at Investor Day

CVS Health Revises Financial Outlook, Showcases Business Strength, and Unveils Bold Strategy to Redefine Health Care at Investor Day CVS Health® will launch its strategy to deliver best-in-class execution, transform consumer experiences, be the partner of choice, and harness unique…

Read MoreCVS Health Revises Guidance, Showcases Business Strength, and Unveils Healthcare Reimagining Strategy at Investor Day

Roche Introduces New CE-Marked PCR Test to Enhance Diagnostic Accuracy for Vaginitis in Women

Roche Introduces New CE-Marked PCR Test to Enhance Diagnostic Accuracy for Women with Vaginitis Roche announced today the CE Mark for its cobas® BV/CV (Bacterial Vaginosis/Candida Vaginitis) assay to accurately identify specific bacteria and yeast responsible for BV and CV…

Read MoreRoche Introduces New CE-Marked PCR Test to Enhance Diagnostic Accuracy for Vaginitis in Women

BRUKINSA Achieves Landmark 74% Six-Year Progression-Free Survival in Treatment-Naïve Chronic Lymphocytic Leukemia Patients

BRUKINSA Achieves Landmark 74% Six-Year Progression-Free Survival in Treatment-Naïve Chronic Lymphocytic Leukemia Patients BeOne Medicines Ltd., a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innovation by showcasing the depth, quality, and momentum of…

Read MoreBRUKINSA Achieves Landmark 74% Six-Year Progression-Free Survival in Treatment-Naïve Chronic Lymphocytic Leukemia Patients

Blueprint Medicines Highlights Long-Term AYVAKIT® Benefits in Systemic Mastocytosis at ASH 2025

Blueprint Medicines presents long-term AYVAKIT® benefits in indolent and advanced systemic mastocytosis at ASH 2025. Blueprint Medicines, a Sanofi company, today announced updated data reinforcing the clinical efficacy and safety of long-term AYVAKIT® (avapritinib) use across the spectrum of systemic mastocytosis (SM),…

Read MoreBlueprint Medicines Highlights Long-Term AYVAKIT® Benefits in Systemic Mastocytosis at ASH 2025

Zoetis Secures Health Canada Approval for Portela™ (relfovetmab Injection) to Relieve Osteoarthritis Pain in Cats

Zoetis Secures Health Canada Approval for Portela™ (relfovetmab Injection) to Relieve Osteoarthritis Pain in Cats Zoetis Inc. today announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three…

Read MoreZoetis Secures Health Canada Approval for Portela™ (relfovetmab Injection) to Relieve Osteoarthritis Pain in Cats

Johnson & Johnson Partners with Naomi Watts to Spotlight Eye Exams as Essential Self-Care for Women Over 40

Johnson & Johnson and Naomi Watts Urge Women Over 40 to Embrace Eye Exams as a Foundational Act of Self-Care Johnson & Johnson Vision—a global leader in eye health—has joined forces with Academy Award–nominated actress, producer, entrepreneur, and women’s health…

Read MoreJohnson & Johnson Partners with Naomi Watts to Spotlight Eye Exams as Essential Self-Care for Women Over 40
Roche

Roche Gets FDA Clearance and CE Mark for First POC Test to Diagnose Whooping Cough

Roche Launches Groundbreaking 15-Minute Point-of-Care Test for Whooping Cough and Other Bordetella Infections, Receiving FDA Clearance, CLIA Waiver, and CE Mark Roche has announced U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laboratory Improvement Amendments of 1988 (CLIA)…

Read MoreRoche Gets FDA Clearance and CE Mark for First POC Test to Diagnose Whooping Cough